SETDB1 and non-small cell lung carcinoma: Furthermore, SETDB1 has been involved in NSCLC progression through WNT–β-catenin pathway stimulation, and for these roles, it was nominated to be a therapeutic target to fight against numerous cancers (Sun et al., 2015).